flufenamic acid has been researched along with edaravone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Jin, H; Jin, Z; Lin, H; Liu, Z; Xu, Q; Yang, W; Yu, P; Zhang, H; Zhang, L; Zhang, Y; Zhao, S | 1 |
2 other study(ies) available for flufenamic acid and edaravone
Article | Year |
---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
Topics: Animals; Cell Line, Tumor; Cinnamates; Glucose; HEK293 Cells; Humans; Infarction, Middle Cerebral Artery; Male; Mice, Inbred C57BL; Molecular Structure; Neuroprotective Agents; ortho-Aminobenzoates; Oxygen; Reperfusion Injury; Structure-Activity Relationship; TRPM Cation Channels | 2021 |